FDA Guidance and Notices, March 2026: Final Guidance on Weight-Loss Devices and Patient Preference Information
Three final guidance documents came out from mid-March 2026 on: premarket considerations for devices with weight-loss indications (March 13), questions and answers on pyrogen and endotoxins testing (March 18), and incorporating voluntary patient preference information over the total product life cycle (March 30). The endotoxins Q&A is worth reading even for teams outside the weight-loss space, since it covers testing relevant to devices.
In the Federal Register on March 18, FDA proposed classifying blood irradiators and setting a date for requiring PMAs for those intended to prevent metastasis. A final order on March 25 reclassified optical diagnostic devices for melanoma detection and electrical impedance spectrometers, renaming them software-aided adjunctive diagnostic devices for use on skin lesions. On March 6, FDA withdrew ten older guidance documents at once, among them microwave oven test procedures and an enforcement policy on positive-beam limitation (PBL) for diagnostic X-ray systems.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles